at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
Company profile
Ticker
AGIO
Exchange
Website
CEO
Jacqualyn Fouse
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AGIOS PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Agios Securities Corporation • Agios Limited • Agios International Sarl • Agios Netherlands B.V. • Agios Germany GmbH • Agios Italy S.R.L. • Agios France SARL ...
AGIO stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
15 Feb 24
8-K
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
15 Feb 24
8-K
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
8 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Agios Reports Business Highlights and Third Quarter 2023 Financial Results
2 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Agios Reports Business Highlights and Second Quarter 2023 Financial Results
3 Aug 23
8-K
Departure of Directors or Certain Officers
14 Jun 23
S-8
Registration of securities for employees
13 Jun 23
8-K
Departure of Directors or Certain Officers
25 May 23
Transcripts
AGIO
Earnings call transcript
2023 Q4
15 Feb 24
AGIO
Earnings call transcript
2023 Q3
2 Nov 23
AGIO
Earnings call transcript
2023 Q2
3 Aug 23
AGIO
Earnings call transcript
2023 Q1
4 May 23
AGIO
Earnings call transcript
2022 Q4
23 Feb 23
AGIO
Earnings call transcript
2022 Q3
4 Nov 22
AGIO
Earnings call transcript
2022 Q2
7 Aug 22
AGIO
Earnings call transcript
2022 Q1
5 May 22
AGIO
Earnings call transcript
2021 Q4
24 Feb 22
AGIO
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
4
Kaye I Foster-Cheek
11 Mar 24
4
Kaye I Foster-Cheek
7 Mar 24
4
Theodore James Jr. Washburn
7 Mar 24
144
Notice of proposed sale of securities
7 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
4
Sarah Gheuens
5 Mar 24
4
Cecilia Jones
5 Mar 24
4
Theodore James Jr. Washburn
5 Mar 24
4
Brian Goff
5 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 64.33 mm | 64.33 mm | 64.33 mm | 64.33 mm | 64.33 mm | 64.33 mm |
Cash burn (monthly) | 6.81 mm | 4.84 mm | 33.63 mm | 32.03 mm | 20.55 mm | 24.14 mm |
Cash used (since last report) | 40.72 mm | 28.97 mm | 201.21 mm | 191.64 mm | 122.93 mm | 144.45 mm |
Cash remaining | 23.61 mm | 35.36 mm | -136.88 mm | -127.31 mm | -58.60 mm | -80.12 mm |
Runway (months of cash) | 3.5 | 7.3 | -4.1 | -4.0 | -2.9 | -3.3 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 146 |
Opened positions | 12 |
Closed positions | 19 |
Increased positions | 55 |
Reduced positions | 44 |
13F shares | Current |
---|---|
Total value | 1.40 tn |
Total shares | 68.15 mm |
Total puts | 325.70 k |
Total calls | 234.70 k |
Total put/call ratio | 1.4 |
Largest owners | Shares | Value |
---|---|---|
Celgene European Investment | 7.12 mm | $242.07 mm |
Vanguard | 5.47 mm | $135.32 bn |
Wellington Management | 5.20 mm | $128.68 bn |
BLK Blackrock | 4.65 mm | $115.11 bn |
BBBOF BB Biotech | 4.03 mm | $0.00 |
BLVGF Bellevue | 4.01 mm | $99.33 bn |
Armistice Capital | 3.32 mm | $82.27 bn |
Farallon Capital Management | 2.75 mm | $68.08 bn |
Rock Springs Capital Management | 2.71 mm | $67.07 bn |
JPM JPMorgan Chase & Co. | 2.47 mm | $61.08 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Mar 24 | Foster-Cheek Kaye I | Common stock | Sell | Dispose S | No | No | 31.62 | 1,285 | 40.63 k | 5,524 |
6 Mar 24 | Foster-Cheek Kaye I | Common stock | Sell | Dispose S | No | No | 31.99 | 4,415 | 141.24 k | 6,809 |
5 Mar 24 | Foster-Cheek Kaye I | Common stock | Sell | Dispose S | No | No | 32.21 | 300 | 9.66 k | 11,224 |
5 Mar 24 | Theodore James Jr. Washburn | Common stock | Sell | Dispose S | No | No | 31.75 | 1,913 | 60.74 k | 2,886 |
5 Mar 24 | Sarah Gheuens | Common stock | Sell | Dispose S | No | Yes | 32.57 | 1,349 | 43.94 k | 39,066 |
5 Mar 24 | Sarah Gheuens | Common stock | Sell | Dispose S | No | Yes | 32.57 | 1,293 | 42.11 k | 36,415 |
5 Mar 24 | Cecilia Jones | Common stock | Sell | Dispose S | No | Yes | 32.57 | 672 | 21.89 k | 14,840 |
1 Mar 24 | Sarah Gheuens | Common stock | Option exercise | Acquire M | No | No | 0 | 4,000 | 0.00 | 40,415 |
1 Mar 24 | Sarah Gheuens | Common stock | Option exercise | Acquire M | No | No | 0 | 3,834 | 0.00 | 37,708 |
1 Mar 24 | Sarah Gheuens | RSU Common stock | Option exercise | Dispose M | No | No | 0 | 4,000 | 0.00 | 8,000 |
News
RBC Capital Maintains Outperform on Agios Pharmaceuticals, Lowers Price Target to $42
16 Feb 24
Agios Pharmaceuticals Q4 Sales $7.10M Miss $7.94M Estimate
15 Feb 24
Earnings Scheduled For February 15, 2024
15 Feb 24
Earnings Preview: Agios Pharmaceuticals
14 Feb 24
Agios Pharmaceuticals Announced Strong Cash Position Expected To Support Completion Of Ongoing Programs And Disciplined Pipeline Expansion At Least Into 2026
8 Jan 24
Press releases
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
15 Feb 24
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
2 Feb 24
Thinking about trading options or stock in Agios Pharmaceuticals, Moderna, Vertex Pharmaceuticals, Applied Materials, or Hut 8?
3 Jan 24
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
3 Jan 24
Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
2 Jan 24